Show Summary Details
Page of

(p. 237) Pharmacological Treatments for Bipolar Disorder 

(p. 237) Pharmacological Treatments for Bipolar Disorder
Chapter:
(p. 237) Pharmacological Treatments for Bipolar Disorder
Author(s):

Paul E. Keck

and Susan L. McElroy

DOI:
10.1093/med:psych/9780199342211.003.0008
Page of

date: 22 February 2020

The majority of clinical trials in patients with bipolar disorders have been conducted in groups with bipolar I illness, although a few trials have included patients with bipolar II disorder. Pharmacological management of bipolar disorder involves the treatment of acute manic, hypomanic, mixed, and depressive episodes, as well as the prevention of further episodes and subsyndromal symptoms. Lithium, divalproex, carbamazepine, haloperidol, risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, and asenapine have demonstrated efficacy in the treatment of acute mania in randomized controlled (type 1) trials. Although the pharmacological treatment of acute bipolar depression remains understudied, data from randomized controlled trials indicate that lithium, olanzapine, olanzapine-fluoxetine, quetiapine, lurasidone, tricyclics, monoamine oxidase inhibitors, and fluoxetine have efficacy in this phase of the illness. Lithium, lamotrigine, olanzapine, aripiprazole, quetiapine, and risperidone (long-acting, injectable) have been shown to have efficacy in relapse prevention. Less extensive data suggest that divalproex and carbamazepine are also efficacious for prevention.

Access to the complete content on Oxford Clinical Psychology requires a subscription or purchase. Public users are able to search the site and view the abstracts and keywords for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.